| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 07/31/2002 | CN1088359C Medicine for curing cerebrovascular disturbance with psychonosema |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426413 Inhibitors of caspases |
| 07/30/2002 | US6426405 Therapeutic target for treatment of diseases associated with altered muscle activity of pain transmission; has properties of glycine transporter associated with strychnine sensitive glycine receptors--properties called ?sc6? activity |
| 07/30/2002 | US6426402 Respiratory system disorders; rheumatic diseases |
| 07/30/2002 | US6426365 CETP activity inhibitors |
| 07/30/2002 | US6426353 α v integrin receptor antagonists |
| 07/30/2002 | US6426341 Treatment for diabetic complications |
| 07/30/2002 | US6426067 Cardiovascular disorders; antitumor agents |
| 07/30/2002 | CA2236021C Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities: process of making metho ds of using and compositions thereof |
| 07/30/2002 | CA2228997C Benzothiophene compounds |
| 07/30/2002 | CA2110806C 4-(1h-pyrrol-1-yl)imidazoles with angiotensin ii antagonist activity |
| 07/30/2002 | CA2104461C Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same |
| 07/25/2002 | WO2002057778A1 Screening assay for cotranslational translocation interfering compounds |
| 07/25/2002 | WO2002057454A2 Receptors and membrane-associated proteins |
| 07/25/2002 | WO2002057453A2 Polypetides and nucleic acids encoding same |
| 07/25/2002 | WO2002057452A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | WO2002057450A2 Proteins and nucleic acids encoding same |
| 07/25/2002 | WO2002057413A2 Peptides for activation and inhibition of delta pkc |
| 07/25/2002 | WO2002057327A1 Method of preparing poly(vinyl pivalate) |
| 07/25/2002 | WO2002057309A1 Novel g protein-coupled receptor protein and dna thereof |
| 07/25/2002 | WO2002057298A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | WO2002057270A1 Inhibitors of cruzipain and other cysteine proteases |
| 07/25/2002 | WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | WO2002057265A1 Compounds substituted with bicyclic amino groups |
| 07/25/2002 | WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors |
| 07/25/2002 | WO2002057257A1 Cyclo`c!azepane derivatives which are used as farnesyltransferase inhibitors and method for the preparation therefor |
| 07/25/2002 | WO2002057242A2 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | WO2002057237A1 Hetero-tricyclic compounds having substituted amino groups |
| 07/25/2002 | WO2002057236A1 Phenyl derivatives |
| 07/25/2002 | WO2002057233A1 Mch antagonists and their use in the treatment of obesity |
| 07/25/2002 | WO2002057230A1 Il-8 receptor antagonists |
| 07/25/2002 | WO2002057226A2 68730 and 69112 protein kinase molecules and uses therefor |
| 07/25/2002 | WO2002057222A2 Thiol-based naaladase inhibitors |
| 07/25/2002 | WO2002057211A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | WO2002056941A2 Method for the treatment of peripheral vascular disease |
| 07/25/2002 | WO2002056915A2 Complex of modafinil and cyclodextrin |
| 07/25/2002 | WO2002056893A1 Novel receptors for $i(helicobacter pylori) and use thereof |
| 07/25/2002 | WO2002056886A1 Angiogenesis inhibitors contaiing urea derivative as the active ingredient |
| 07/25/2002 | WO2002056880A1 Triphenylmethane kinesin inhibitors |
| 07/25/2002 | WO2002056875A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance |
| 07/25/2002 | WO2002056874A2 Lipid-based nitric oxide donors |
| 07/25/2002 | WO2002056873A2 2-substituted dibenzo[a,e]1,2,3-triazolo[4,5-c][7]annulen-8-ones as growth hormone secretagogues |
| 07/25/2002 | WO2002056864A2 Differential delivery of nitric oxide |
| 07/25/2002 | WO2002056837A2 Inhibition of protein-phosphatases for the treatment of heart failure |
| 07/25/2002 | WO2002056827A2 Substituted felbamate derived compounds |
| 07/25/2002 | WO2002056790A2 Delivery of therapeutic capable agents |
| 07/25/2002 | WO2002056753A2 P27 prevents cellular migration |
| 07/25/2002 | WO2002056708A2 Preparation for improved dietary utilisation |
| 07/25/2002 | WO2002056692A1 Methods for modulating tumor growth and metastasis |
| 07/25/2002 | WO2002039988A3 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 07/25/2002 | WO2002032901A3 Bridged piperazine derivatives |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/25/2002 | WO2002030874A3 Aliphatic, cyclic amino carboxylic acids as integrin antagonists |
| 07/25/2002 | WO2002018379A3 7-oxo pyridopyrimidines |
| 07/25/2002 | WO2002015886A3 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 07/25/2002 | WO2002014320A3 Novel substituted diaryl azepine derivatives as integrin ligands |
| 07/25/2002 | WO2002012461A3 Regulation of human membrane-type serine protease |
| 07/25/2002 | WO2002008177A3 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 07/25/2002 | WO2001094413A3 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 07/25/2002 | WO2001092891A3 Regulating lipid levels via the zmax1 or hbm gene |
| 07/25/2002 | WO2001090091A8 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 07/25/2002 | WO2001088126A3 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 07/25/2002 | WO2001078701A3 Method and compositions for preventing hormone induced adverse effects |
| 07/25/2002 | WO2001070798A3 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 07/25/2002 | WO2001070222A3 Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 07/25/2002 | WO2001057208A3 Mlp gene, nucleic acids, polypeptides and the utilization thereof |
| 07/25/2002 | WO2001015676A3 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 07/25/2002 | WO2001004157A9 NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS |
| 07/25/2002 | WO2001002567A9 16405 receptor, a g-protein coupled receptor |
| 07/25/2002 | WO2001000812A9 22012, a novel human carboxypeptidase |
| 07/25/2002 | US20020100069 Treating heart defects; obtain tissue, incubate with modulator of transcription, evaluate tissue for defect |
| 07/25/2002 | US20020099357 Ocular iontophoretic device and method for using the same |
| 07/25/2002 | US20020099322 Adhering therapeutic tool |
| 07/25/2002 | US20020099222 Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 07/25/2002 | US20020099209 Dihydrostilbene alkanoic acid derivatives |
| 07/25/2002 | US20020099207 Has activity as an antagonist to neurokinin 1 receptors; for therapy of benign prostatic hyperplasia (BPH) |
| 07/25/2002 | US20020099191 EDG8 receptor, its preparation and use |
| 07/25/2002 | US20020099175 Methods for the synthesis of a modified hemoglobin solution |
| 07/25/2002 | US20020099097 Pharmaceutical solutions of modafinil compounds |
| 07/25/2002 | US20020099071 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia |
| 07/25/2002 | US20020099068 I kappa B kinase inhibitors for treating various disorders including arthritis |
| 07/25/2002 | US20020099057 Treatment of accidental extravasation of anthracyclines |
| 07/25/2002 | US20020099054 2-phenyl benzimidazole derivatives as MCP-1 antagonists |
| 07/25/2002 | US20020099046 Atorvastatin or a pharmaceutically acceptable salt thereof and an antihypertensive agent such as a calcium channel blocker, an ACE inhibitor, an A-II antagonist, a diuretic, a beta- or alpha adrenergic receptor blocker |
| 07/25/2002 | US20020099030 Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties |
| 07/25/2002 | US20020099029 Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| 07/25/2002 | US20020099010 Neurogenic compositions and methods |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | US20020098998 P27 prevents cellular migration |
| 07/25/2002 | US20020098550 Nucleotide sequences coding membrane protein for use in treatment and prevention of endotoxin shock, viral disease, immflammation and tumors |
| 07/25/2002 | US20020098540 Novel polypeptides, and nucleic acids encoding the same |
| 07/25/2002 | US20020098278 Coated implantable medical device |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098166 Genetically modified cells and their use in the prophylaxis or therapy of disorders |
| 07/25/2002 | DE10102944A1 Production of 3-cyano-1H-indol-7-yl)-(4-(4-fluorophenethyl)piperazin-1-yl)-methanone useful as a selective 5-HT2A antagonist comprises use of an indolecarboxylic acid ester as the starting material |
| 07/25/2002 | DE10102322A1 New disubstituted and trisubstituted benzene derivatives useful as coagulation inhibitors for the treatment of thromboembolic diseases |
| 07/25/2002 | DE10101522A1 Composition for treating collagenase-linked degenerative diseases, e.g. atherosclerosis, cancer and infections, comprises ascorbate and a fibrinolysis inhibitor |
| 07/25/2002 | CA2443895A1 Differential delivery of nitric oxide |
| 07/25/2002 | CA2443080A1 Lipid-based nitric oxide donors |